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ABSTRACT
Coronavirus disease 19 (COVID-19) is a worldwide infection which was recently declared a global health emergency by the WHO 
Emergency Committee. The most common symptoms are fever and cough, which can progress to pneumonia, acute respiratory distress 
syndrome (ARDS) and/or end-organ failure. Risk factors associated with ARDS and death are older age, comorbidities (e.g., hypertension, 
diabetes, hyperlipidaemia), neutrophilia, and organ and coagulation dysfunction. Disseminated intravascular coagulation and coagulopathy 
can contribute to death. Anticoagulant treatment is associated with decreased mortality in severe COVID-19 pneumonia. In this report we 
describe two patients with COVID-19 pneumonia who developed venous thromboembolism.
LEARNING POINTS
• Deep vein thrombosis and pulmonary embolism can occur in patients with COVID-19 pneumonia.
• Low-molecular-weight heparin prophylaxis does not decrease the risk of venous thromboembolism (VTE) in COVID-19 pneumonia.
• In the presence of clinical signs and/or suspicion of VTE, compression ultrasound and echocardiography should be always performed, 
irrespective of disease stage.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a viral infection which has spread rapidly throughout the world and was declared a global health 
emergency by the WHO Emergency Committee in January 2020. Dry cough and fever are the most common symptoms of COVID-19 
infection, which can progress to pneumonia, acute respiratory distress syndrome (ARDS) and end-organ failure[1]. Risk factors for ARDS 
and death are older age, comorbidities (hypertension, diabetes), neutrophilia, lymphocytopenia, elevated inflammatory indices (C-reactive 
protein, serum ferritin), and organ (AST, albumin, creatinine, urea, LDH) and coagulation dysfunction (PT and D-dimer). In addition, patients 
with underlying cardiovascular disease can have an adverse prognosis[2]. Diagnosis of COVID-19 encompasses a mixture of clinical suspicion 
and imaging techniques, including point-of care lung ultrasound (US) and a chest CT scan[3].
The pathogenesis of COVID-19 infection is not clearly understood. Inflammatory cytokine storms and viral evasion of cellular immune 
responses play a central role in disease progression and severity[4]. 
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A combination of antiviral and anti-inflammatory treatments could be useful to avoid ARDS and multiple organ failure[5]. Coagulopathy and 
disseminated intravascular coagulation are common complications of severe COVID-19 pneumonia and the most common causes of death[6]. 
Recently, the sepsis-induced coagulopathy (SIC) score has been proposed as a new score for patients with sepsis and coagulopathy[7], and 
the administration of heparin (mainly low-molecular-weight heparin, LMWH) has been demonstrated to be associated with decreased 
mortality in patients with severe COVID-19 with SIC criteria or with markedly elevated D-dimer[8]. At the time of writing, there have been 
no previous reports of deep vein thrombosis (DVT) or pulmonary embolism (PE) in COVID-19 pneumonia. We describe two cases of venous 
thromboembolism (VTE) in patients with COVID-19 pneumonia.
CASE DESCRIPTION
Case 1
An 82-year-old woman was admitted to our emergency department (ED) for a 5-day history of fever and general malaise. The patient was on 
oral azithromycin and amoxicillin-clavulanate without any improvement. She was an ex-smoker and had a medical history of hypertension 
and chronic obstructive pulmonary disease. At admission she presented severe respiratory failure (PaO2/FiO2 55 mmHg, respiratory rate 
26 breaths/min) with a need for high-flow oxygen therapy. A lung ultrasound (US) showed diffuse B lines with pleural thickening and 
small subpleural consolidations. A chest CT scan and nasopharyngeal swab confirmed the diagnosis of COVID-19 pneumonia. Laboratory 
findings, including the SIC score, are reported in Table 1. Antibiotics were discontinued, and darunavir/cobicistat, hydroxychloroquine and 
LMWH at a prophylactic dose were started.
On day 12 after admission, the patient complained of an ache in her right leg and a sensation of warmth. She denied chest pain and 
dyspnoea (PaO2/FiO2 >300 mmHg on nasal prong oxygen). Physical examination revealed oedema of the right leg and signs of dehydration.
Compression ultrasound (CUS) of the right common femoral vein indicated venous thrombosis (Fig. 1). Lung US showed multiple bibasal 
consolidations (Fig. 2). Echocardiography documented normal ventricular function in the absence of indirect signs of PE. The inferior vena 
cava had completely collapsed, indicating hypovolemia. An electrocardiogram (ECG) revealed sinus tachycardia. Blood tests showed elevated 
D-dimer (24 131 mg/dl), fibrinogen (674 mg/dl), serum ferritin (765 ng/ml) and troponin I (57 ng/ml) (Table 1). As creatinine clearance was 
≤30 ml/min, continuous intravenous infusion of unfractionated heparin was started with close monitoring of partial thromboplastin time 
(PTT). The patient underwent a CT scan of the chest that showed diffuse bilateral consolidations and a crazy-paving pattern (visual CT 
score 70%) (Fig. 3). Based on this finding, we introduced systemic corticosteroids. The patient is still recovering at the time of writing. Her 
clinical condition is progressively improving with complete resolution of acute renal failure after infusion of crystalloid fluids (Table 1). She 
needs only low-flow oxygen therapy. The heparin infusion was switched after 3 days to standard-dose LMWH (enoxaparin). 
Figure 1. Compression ultrasound shows the incompressibility of 
the right common femoral vein
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Figure 2. Point-of-care lung ultrasound. The image 
shows multiple basal consolidations
Figure 3. Lung CT scan. The image shows multiple ground-glass opacities and 
consolidations in both lungs
Case 2
A 64-year-old man was admitted to our ED complaining fever and dry cough treated with antibiotics over the previous 10 days. Point-
of-care lung US revealed diffuse B lines with bibasal consolidations which were also documented by chest x-ray. A nasopharyngeal swab 
confirmed the diagnosis of COVID-19 pneumonia. Laboratory findings at diagnosis are reported in Table 2. The patient’s medical history 
was unremarkable, and he did not take any medications. Right bundle branch block (RBB) was detected on ECG. He was treated with 
darunavir/cobicistat, hydroxychloroquine, LMWH at a prophylactic dose and low-flow nasal prong oxygen. He was discharged after 10 
days in good health with no need for oxygen. His SIC score was below 4, so LMWH administration was stopped. However, after 1 week 
the patient again presented to our ED with complaints of acute chest pain while breathing (SpO2 97%, PaO2/FiO2 341 mmHg on ambient 
air), and an ache in his left leg for the last 3 days. He denied previous venous thrombosis or a family history of thrombophilia. The clinically 
suspected DVT was confirmed by CUS with no compressibility of the left popliteal vein. Echocardiography was normal. Lung US showed 
focal B lines and left basal consolidation with slight pleural effusion (Fig. 4). ECG results were unchanged (NSR, RBBB). CT pulmonary 
angiography documented left subsegmental PE with diffuse ground-glass opacity and a crazy-paving pattern (visual CT score 5%) (Fig. 5). 
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Laboratory findings are reported in Table 2. Interestingly, the SIC score was normal [3]. Another nasopharyngeal swab was taken and showed 
low-positive results. Fondaparinux was immediately started at a high dose and switched to a twice daily regimen of dabigatran after 5 days. 
The patient was discharged without sequelae on day 6.
Figure 5. Left subsegmental pulmonary embolism on CT pulmonary angiography
Figure 4. Point-of-care lung ultrasound. The image shows left basal 
consolidations with slight pleural effusion
DISCUSSION
VTE is a significant cause of morbidity and mortality. Risk factors include older age, immobilization, obesity, smoking and hospitalization. 
COVID-19 patients frequently complain of severe asthenia, fatigue and consequent inactivity, even at the beginning of the infection. In 
addition, risk factors for VTE include hypoxia and sepsis[9], which are two common features of COVID-19. Anticoagulant treatment is 
associated with decreased mortality in severe COVID-19 pneumonia[8], but no data have been reported in the literature for the different 
stages of COVID-19 infection. Furthermore, D-dimer is not a useful marker for diagnosing VTE in COVID-19, because it is generally 
increased, particularly in severe COVID-19 pneumonia, and is associated with the development of ARDS and progression from ARDS 
to death[1]. Based on all this evidence, if there are clinical signs and/or suspicion of VTE, CUS and echocardiography should always be 
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Table 1. Patient’s laboratory findings at 
admission and during recovery
ALT, alanine transaminase; AST, aspartate 
transaminase; CRP, C-reactive protein; LDH, 
lactate dehydrogenase; NC, nasal cannula; 
ND, not done; PCT, procalcitonin; PLT, 
platelet; PT, prothrombin time; PTT, partial 
thromboplastin time; SIC, sepsis-induced 
coagulopathy; WBC, white blood cell count. 
Abnormal values are in red. 
At admission Recovery day 12 Recovery day 15 (day 3 of heparin infusion)
WBC (4-10x109/l) 10.26 13.06 12.28
Neutrophil count (2-8x109/l) 6.56 9.73 9.25
Lymphocitye count (1.5-4x109/l) 1.02 0.56 0.51
PLT count (150-450x109/l) 170 200 203
PT-INR 170 200 203
PTT sec 170 200 203
CRP (<0.5 mg/dl) 20.4 13.81 11.98
PCT (<0.5 ng/ml) ND ND 0.48
Fibrinogen (150–400 mg/dl) ND 674 ND
D-dimer (<500 ng/ml) ND 24 131 7120
Troponin I (<31 ng/l) ND 57 ND
LDH (0–248 U/l) NA 589 514
Serum ferritin (150–400 ng/ml) ND 765 1286
Creatinine (0.6–1.2 mg/dl) 1.31 3.22 0.99
Blood urea nitrogen (10–50 mg/dl) 93 264 95
Potassium (3.5–5.0 mEq/l) 4.7 5.1 3.1
AST (10-37 U/l) 56 43 61
ALT (10-37 U/l) 21 15 28
Total bilirubin (0.1–1.1 mg/dl) 1.3 1.31 1.25
PaO2/FiO2 (mmHg) 55 (room air) >300 (NC 6 l/min) >350 (NC 4 l/min)
SIC score (≥4) 4 5 ND
performed, irrespective of disease stage. Our findings suggest that patients with COVID-19 pneumonia should be investigated for VTE 
even if treated with LMWH. [Q5]Both our patients seemed to be at risk of VTE even in the absence of hypoxaemia and severe respiratory 
failure, and it is clear VTE can increase the risk of death in COVID-19 patients.
Accurate knowledge of COVID-19 pathophysiology will be important in predicting and preventing VTE, and further studies are necessary 
to evaluate whether the SIC score can guide the decision to initiate anticoagulant therapy in COVID-19. Based on our experience, we 
believe that LMWH therapy at a prophylactic dose should be carefully considered in all patients with COVID-19 pneumonia for a longer 
period than required for clinical resolution of the disease.
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At diagnosis of 
COVID-19 
pneumonia
At discharge At re-admission to ED At discharge
WBC (4-10x109/l) 3.85 7.0 11.95 6.04
Neutrophil count (2-8x109/l) 2.49 5.49 9.99 4.4
Lymphocitye count (1.5-4x109/l) 1.02 0.93 1.07 0.93
PLT count (150-450x109/l) 183 360 272 246
PT-INR 1.51 1.49 1.34 1.42
PTT sec 31.8 31.1 27.0 34.9
CRP (<0.5 mg/dl) 10.57 0.71 11.52 7.93
PCT (<0.5 ng/ml) 0.04 0.02 ND ND
Fibrinogen (150–400 mg/dl) 552 ND ND 820
D-dimer (<500 ng/ml) ND ND 1167 3440
LDH (0–248 U/l) 291 227 201 204
Troponin I (<31 ng/l) ND ND 3.6 ND
Creatinine (0.6–1.2 mg/dl) 1.04 0.68 0.87 0.8
Blood urea nitrogen (10–50 mg/dl) 35 35 30 42
Potassium (3.5–5.0 mEq/l) 3.8 5.0 4.0 5.5
AST (10-37 U/l) 38 29 18 21
ALT (10-37 U/l) 21 51 26 23
Total bilirubin (0.1–1.1 mg/dl) 0.63 0.54 0.76 0.55
PaO2/FiO2 (mmHg) 304 341 323 350
SIC score (≥4) 3 3 2 ND
Table 2. Patient’s laboratory findings at admission and during recovery
ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; ED, emergency department; LDH, lactate dehydrogenase; ND, not done; PCT, procalcitonin; PLT, 
platelet; PT, prothrombin time; PTT, partial thromboplastin time; SIC, sepsis-induced coagulopathy; WBC, white blood cell count. Abnormal values are in red. 
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